Remibrutinib is primarily used in the development of treatments for autoimmune diseases. It acts as a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), which plays a crucial role in the signaling pathways of B cells and other immune cells. By inhibiting BTK, remibrutinib helps to modulate the immune response, making it particularly effective in conditions where abnormal B cell activity is a contributing factor. Clinical trials have explored its application in diseases such as chronic spontaneous urticaria, multiple sclerosis, and rheumatoid arthritis. Its targeted mechanism offers the potential for reduced side effects compared to broader immunosuppressive therapies, providing a more precise approach to managing autoimmune disorders.